Patent · US Active

Pulsed introduction of low-dose RANKL as a therapy for diet-induced atherosclerosis

US10745461B2 · kind B2 · utility

0Cited by
2References
9Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 10, 2018
Grant dateAug 18, 2020
Priority date—
Expiry dateOct 28, 2038

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P9/10
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Systems and methods for inhibiting atherosclerosis using FoxP3+ CD8 T-cells (TcREG). Osteoclasts are induced to produce FoxP3+ CD8 T-cells (TcREG) through introduction of a low-dose of a RANK agonist such as RANKL. The RANKL was found to best work when provided in accordance with a schedule resulting in a pulsed administration.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.